CN116870047A - Composite medicament for inhibiting respiratory syncytial virus and preparation method thereof - Google Patents
Composite medicament for inhibiting respiratory syncytial virus and preparation method thereof Download PDFInfo
- Publication number
- CN116870047A CN116870047A CN202311009766.1A CN202311009766A CN116870047A CN 116870047 A CN116870047 A CN 116870047A CN 202311009766 A CN202311009766 A CN 202311009766A CN 116870047 A CN116870047 A CN 116870047A
- Authority
- CN
- China
- Prior art keywords
- traditional chinese
- syncytial virus
- respiratory syncytial
- chinese medicine
- inhibiting respiratory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 148
- 241000725643 Respiratory syncytial virus Species 0.000 title claims abstract description 28
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 27
- 239000002131 composite material Substances 0.000 title claims description 15
- 238000002360 preparation method Methods 0.000 title abstract description 14
- 230000000694 effects Effects 0.000 claims abstract description 44
- 241000700605 Viruses Species 0.000 claims abstract description 27
- 239000008213 purified water Substances 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000000463 material Substances 0.000 claims abstract description 18
- 230000000144 pharmacologic effect Effects 0.000 claims abstract description 16
- 239000004480 active ingredient Substances 0.000 claims abstract description 15
- 229920002261 Corn starch Polymers 0.000 claims abstract description 13
- 239000008120 corn starch Substances 0.000 claims abstract description 13
- 238000002156 mixing Methods 0.000 claims description 32
- 238000003756 stirring Methods 0.000 claims description 32
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 9
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 9
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 9
- 235000019800 disodium phosphate Nutrition 0.000 claims description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 9
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 9
- 239000001488 sodium phosphate Substances 0.000 claims description 9
- 239000000853 adhesive Substances 0.000 claims description 8
- 230000001070 adhesive effect Effects 0.000 claims description 8
- 238000000227 grinding Methods 0.000 claims description 8
- 239000012535 impurity Substances 0.000 claims description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 7
- 244000144725 Amygdalus communis Species 0.000 claims description 6
- 235000011437 Amygdalus communis Nutrition 0.000 claims description 6
- 241001061264 Astragalus Species 0.000 claims description 6
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 6
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 6
- 244000274050 Platycodon grandiflorum Species 0.000 claims description 6
- 235000020224 almond Nutrition 0.000 claims description 6
- 235000006533 astragalus Nutrition 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 210000004233 talus Anatomy 0.000 claims description 6
- 240000008397 Ganoderma lucidum Species 0.000 claims description 5
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 5
- 235000006753 Platycodon grandiflorum Nutrition 0.000 claims description 5
- KZFDVWZZYOPBQZ-UHFFFAOYSA-K bismuth;potassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KZFDVWZZYOPBQZ-UHFFFAOYSA-K 0.000 claims description 5
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 5
- 235000011477 liquorice Nutrition 0.000 claims description 5
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical group CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims description 5
- 229960003752 oseltamivir Drugs 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 241001180876 Saposhnikovia Species 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000002831 pharmacologic agent Substances 0.000 claims description 3
- 241000222336 Ganoderma Species 0.000 claims description 2
- 239000009636 Huang Qi Substances 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 22
- 229940079593 drug Drugs 0.000 abstract description 16
- 210000002345 respiratory system Anatomy 0.000 abstract description 14
- 230000036039 immunity Effects 0.000 abstract description 10
- 238000011084 recovery Methods 0.000 abstract description 6
- 206010067484 Adverse reaction Diseases 0.000 abstract description 5
- 230000006838 adverse reaction Effects 0.000 abstract description 5
- 230000001988 toxicity Effects 0.000 abstract description 5
- 231100000419 toxicity Toxicity 0.000 abstract description 5
- 230000001965 increasing effect Effects 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 3
- 230000010076 replication Effects 0.000 abstract description 3
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 3
- 230000014599 transmission of virus Effects 0.000 abstract description 3
- 210000004072 lung Anatomy 0.000 description 15
- 208000023504 respiratory system disease Diseases 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 9
- 230000006872 improvement Effects 0.000 description 8
- 206010011224 Cough Diseases 0.000 description 6
- 229940126673 western medicines Drugs 0.000 description 6
- 244000046146 Pueraria lobata Species 0.000 description 5
- 235000010575 Pueraria lobata Nutrition 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000004199 lung function Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 241000711920 Human orthopneumovirus Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 235000006751 Platycodon Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000226 anti-syncytial effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229930189914 platycodon Natural products 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940043263 traditional drug Drugs 0.000 description 1
- 230000006656 viral protein synthesis Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the technical field of respiratory tract compound medicaments, in particular to a compound medicament for inhibiting respiratory tract syncytial virus and a preparation method thereof. The traditional Chinese medicine composition comprises a traditional Chinese medicine component A, a traditional Chinese medicine component B, a pharmacological active component, corn starch, auxiliary materials and purified water; the compound medicament prepared by the invention combines the characteristics of traditional Chinese medicines and modern medicines to enhance the curative effect of the medicines and reduce toxicity and side effects, and the added traditional Chinese medicine components have the effects of resisting viruses and regulating immunity and can enhance the curative effect of the medicines; the added pharmacological active ingredients can help to inhibit the replication and transmission of viruses, so that the recovery speed is increased; not only can better inhibit the virus amount of respiratory syncytial virus, but also reduces adverse reaction and side effect of the drug to children patients.
Description
Technical Field
The invention relates to the technical field of respiratory tract compound medicaments, in particular to a compound medicament for inhibiting respiratory tract syncytial virus and a preparation method thereof.
Background
For respiratory diseases caused by respiratory syncytial virus, traditional drug treatment does not completely solve the pain of patients. Most of the current pediatric respiratory drugs mainly include bronchodilators, respiratory system agonists, antiallergic drugs, etc., and although these drugs can alleviate the symptoms of patients in a certain way, there are many disadvantages such as adverse effects of the drugs on the body of children, unstable drug effects, recurrent attacks of patients, etc.
For western medicines, although having the characteristics of broad-spectrum bacillus antibiotics, the western medicines often cause drug resistance and side effects of medicines, such as gastrointestinal discomfort, allergy, dizziness, liver injury, kidney injury and the like. In addition, because the sensitivity degree of different pathogens to western medicines is different, the treatment effect of the western medicines is different, and the problems faced by pediatric respiratory diseases can not be fundamentally solved by using the western medicines only.
On the other hand, although the traditional Chinese medicine has many advantages of treating children respiratory diseases, such as stable curative effect, less side effects, strong pharmacological effects and the like, the traditional Chinese medicine also has some problems. Firstly, the traditional Chinese medicine often needs to be processed more to prepare the preparation formulation, and the operation difficulty is high. Secondly, the traditional Chinese medicine contains a large amount of active ingredients and is complex, and adverse reactions to human bodies can be generated when the dosage is improper or the compatibility is improper. In addition, the traditional Chinese medicine is used as a natural medicine, and the ingredients of each batch are different.
In summary, the problems of treating children respiratory diseases by adopting western medicines or traditional Chinese medicines are obvious, and a compound medicament capable of inhibiting respiratory syncytial viruses is needed to overcome the defects in the prior art.
Disclosure of Invention
The present invention is directed to a compound pharmaceutical agent for inhibiting respiratory syncytial virus and a preparation method thereof, so as to solve the problems set forth in the background art.
In order to achieve the aim, the medicament adopts Chinese medicinal components and western medicinal components, wherein the Chinese medicinal components such as astragalus, platycodon grandiflorum, kudzuvine root and the like can enhance the immune function of a human body and improve the symptoms of pediatric respiratory diseases; western medicine components such as oseltamivir and bismuth potassium citrate can control the spread and spread of viruses by inhibiting the interaction between viral protein synthesis and membrane glycoproteins. The compound medicine can inhibit the virus amount of respiratory syncytial virus well and reduce the adverse reaction and side effect of the medicine to children.
In one aspect, the invention provides a combination agent for inhibiting respiratory syncytial virus, comprising the following raw materials:
the traditional Chinese medicine component A accounts for 20-40% of the total mass;
the traditional Chinese medicine component B accounts for 10-20% of the total mass;
pharmacologically active ingredients, accounting for 5-15% of the total mass;
corn starch accounting for 3-5% of the total mass;
auxiliary materials accounting for 4-10% of the total mass;
the balance being purified water.
As a further improvement of the technical scheme, the traditional Chinese medicine component A comprises astragalus, platycodon grandiflorum and kudzuvine root.
As a further improvement of the technical scheme, the weight ratio of the astragalus, the platycodon grandiflorum and the kudzuvine root is 6:2:1.
As a further improvement of the technical scheme, the traditional Chinese medicine component B comprises liquorice, almond, ganoderma lucidum and radix sileris.
As a further improvement of the technical scheme, the weight ratio of the liquorice to the almond to the ganoderma lucidum to the divaricate saposhnikovia root is 2:2:2:1.
As a further improvement of the technical scheme, the pharmacological active ingredient adopts a virus inhibitor, which is suitable for inhibiting respiratory syncytial virus; the virus inhibitor is selected from oseltamivir and bismuth potassium citrate.
As a further improvement of the technical scheme, the auxiliary materials comprise microcrystalline cellulose, disodium phosphate, polyethylene glycol 6000 and magnesium stearate.
As a further improvement of the technical scheme, the weight ratio of the microcrystalline cellulose to the disodium phosphate to the polyethylene glycol 6000 to the magnesium stearate is 2:0.2:2:2.
In another aspect, the present invention provides a method for preparing a complex agent for inhibiting respiratory syncytial virus according to any one of the above, comprising the steps of:
s1, respectively grinding the traditional Chinese medicine component A and the traditional Chinese medicine component B into fine powder, and uniformly mixing;
s2, adding the combined powder of the traditional Chinese medicine components A and B into corn starch, stirring and mixing uniformly, gradually adding purified water, and stirring and mixing simultaneously until a uniform and non-adhesive paste is formed;
s3, adding the pharmacological active ingredients into the paste, continuously stirring and mixing, then adding auxiliary materials, and continuously stirring until a uniform medicament solution is formed;
s4, adding purified water to adjust the concentration of the medicament solution, and centrifuging the medicament solution filter box by utilizing a filter and a high-speed centrifuge to remove impurities so as to achieve the composite medicament with better purity and activity.
Compared with the prior art, the invention has the beneficial effects that:
1. in the compound medicament for inhibiting the respiratory syncytial virus and the preparation method thereof, the characteristics of traditional Chinese medicines and modern medicines are combined to enhance the curative effect of the medicines and reduce toxicity and side effects, and the added traditional Chinese medicine components (A and B) are common traditional Chinese medicinal materials, have the effects of resisting viruses and regulating immunity, and can enhance the curative effect of the medicines; the added pharmacological active ingredients can help to inhibit the replication and transmission of viruses, so that the recovery speed is increased; the added auxiliary materials can increase the degradation stability, uniformity and taste of the medicine, the microcrystalline cellulose in the medicine can improve the solubility and bioavailability of the medicine, the disodium phosphate is used for adjusting the pH value of the medicine, and the magnesium stearate can reduce the toxicity of the medicine and improve the taste.
2. According to the compound medicament for inhibiting the respiratory syncytial virus and the preparation method thereof, the compound medicament not only can better inhibit the viral load of the respiratory syncytial virus, but also reduces adverse reaction and side effect of the medicament on children patients.
Drawings
Fig. 1 is an overall flow diagram of the present invention.
Detailed Description
The following description of the embodiments of the present invention will be made clearly and completely with reference to the accompanying drawings, in which it is apparent that the embodiments described are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
The embodiment of the invention provides a compound medicament for inhibiting respiratory syncytial virus, which comprises the following raw materials:
the traditional Chinese medicine component A accounts for 20-40% of the total mass;
the traditional Chinese medicine component B accounts for 10-20% of the total mass;
pharmacologically active ingredients, accounting for 5-15% of the total mass;
corn starch accounting for 3-5% of the total mass;
auxiliary materials accounting for 4-10% of the total mass;
the balance being purified water.
The Chinese medicinal component A comprises astragalus root, platycodon root and kudzuvine root according to the weight ratio of 6:2:1; the astragalus has the effects of tonifying qi, strengthening the surface, enhancing immunity and the like, and can effectively improve the resistance of a human body, thereby playing roles of resisting viruses and preventing diseases; the platycodon grandiflorum has the effects of moistening lung, resolving phlegm, relieving cough and asthma, and can effectively improve respiratory symptoms, so that illness is relieved; the kudzuvine root has the effects of detoxification, heat clearing, fluid production promoting, lung moistening and the like, can accelerate the excretion of viruses, and can relieve the symptoms of cough, fever and the like; for pediatric respiratory diseases, the traditional Chinese medicine component A has more remarkable curative effects, children are very easy to infect viruses because the immune system is not fully developed and has weak resistance, and symptoms are usually more serious, the astragalus is rich in a plurality of amino acids, saccharides, polyphenol and other composite substances, the radix astragali has good health care effect on the bodies of the children, the radix platycodonis can relieve symptoms and prevent the disease deterioration, and the radix puerariae has the curative effects of clearing heat and detoxicating, resolving phlegm and relieving cough, moistening lung and tonifying qi and the like, and can thoroughly assist in treating respiratory diseases;
in conclusion, the formula in the traditional Chinese medicine component A is matched with each other, so that the traditional Chinese medicine component A can play a synergistic effect, enhance the body immunity, relieve and control the symptoms of the respiratory diseases of children, and simultaneously reduce the adverse reaction of medicines, thereby being a good treatment formula for treating the respiratory diseases of children.
The traditional Chinese medicine component B comprises liquorice, almond, ganoderma lucidum and divaricate saposhnikovia root in a weight ratio of 2:2:2:1; the licorice has the effects of resisting inflammation, relieving cough, moistening lung and the like, can relieve symptoms such as sore throat, excessive phlegm and the like, reduces the resistance of the lung, and has good moisturizing and lubricating effects; the almond is rich in nutrient substances such as grease, vitamins and the like, has the effects of tonifying qi, moistening lung, relieving asthma and the like, can improve the immunity of respiratory tracts and the phlegm eliminating effect, and accelerates the excretion and recovery of lungs; the ganoderma lucidum has multiple effects of improving immunity, regulating respiratory tract, resisting inflammation, resisting oxidation and the like, and can strengthen the immunity of the body to viruses and bacteria, thereby helping the body resist respiratory tract infection and viruses; the radix sileris has the effects of dispelling wind, relieving sore throat, dispelling cold, inducing perspiration and the like, has the effects of clearing heat and detoxicating, and can enhance the resistance of the lung; aiming at pediatric respiratory diseases, the traditional Chinese medicine component B has unique treatment effect; because the respiratory tract immunity of children is weaker, cough, asthma and other symptoms are very easy to occur, liquorice, almond and lucid ganoderma are matched with each other, so that the immunity of the body can be enhanced, the excretion and recovery of viruses and bacteria can be promoted, the wind prevention can dispel dampness and dispel cold, and the lung cold can be eliminated by matching with the wind prevention, and the lung function can be adjusted;
in conclusion, the formula of the traditional Chinese medicine component B is matched with each other, so that the traditional Chinese medicine component B can play a synergistic effect, strengthen the immunity of the body, regulate the lung function, alleviate symptoms and have more pertinence and uniqueness for the treatment of pediatric respiratory diseases.
The pharmacological active ingredient adopts a virus inhibitor, and is suitable for inhibiting respiratory syncytial virus; the virus inhibitor is selected from oseltamivir and bismuth potassium citrate, and can effectively inhibit the spread of respiratory syncytial virus by adding oseltamivir or bismuth potassium citrate, thereby achieving the aims of prevention and treatment.
Corn starch is a high molecular polymer, and is used as a filler and a diluent of a composite medicament to ensure the stability and the drug effect of the medicament.
The auxiliary materials comprise microcrystalline cellulose, disodium phosphate, polyethylene glycol 6000 and magnesium stearate in a weight ratio of 2:0.2:2:2; microcrystalline cellulose is mainly used as a filling agent and a stabilizing agent of the preparation, and can strengthen the release effect and stability of the medicine; the disodium phosphate can adjust the pH value of the preparation, and ensure the stability and the drug effect of the compound preparation; polyethylene glycol 6000 is mainly used for keeping the physical properties of the medicine, improving the taste and permeability of the medicine and improving the medicine efficacy absorption rate; the magnesium stearate can enhance the stability of the preparation and improve the texture and taste of the medicine;
the auxiliary ingredients can be matched to effectively improve the stability and compatibility of the medicine, and can play a role in relieving the symptoms of respiratory diseases such as asthma, bronchitis and the like for pediatric respiratory diseases; meanwhile, the traditional Chinese medicine composition also has the special effects of preventing bronchospasm, relieving cough symptoms and the like.
The compound medicament provided by the invention is a compound medicament combining traditional Chinese medicine and western medicine, combines the characteristics of traditional Chinese medicine and modern medicine, enhances the curative effect of the medicament, reduces toxicity and side effect, and has antiviral and immunoregulatory effects by adding the traditional Chinese medicine components (A and B) which are common traditional Chinese medicinal materials, so that the curative effect of the medicament can be enhanced; the added pharmacological active ingredients can help to inhibit the replication and transmission of viruses, so that the recovery speed is increased; the added auxiliary materials can increase the degradation stability, uniformity and taste of the medicine, the microcrystalline cellulose in the medicine can improve the solubility and bioavailability of the medicine, the disodium phosphate is used for adjusting the pH value of the medicine, and the magnesium stearate can reduce the toxicity of the medicine and improve the taste;
in summary, the advantages of the composite agent provided by the present invention include: the combination of traditional Chinese medicine and western medicine has antiviral, immunoregulation, drug stability increasing, drug solubility and bioavailability improving, drug pH adjusting, drug toxicity reducing, and taste improving effects.
According to fig. 1, the embodiment of the invention also provides a preparation method for preparing the composite medicament for inhibiting respiratory syncytial virus, which comprises the following specific steps:
(1) Grinding the traditional Chinese medicine component A and the traditional Chinese medicine component B into fine powder respectively, and uniformly mixing;
(2) Adding the combined powder of the traditional Chinese medicine components A and B into corn starch, stirring and mixing uniformly, gradually adding purified water, and stirring and mixing simultaneously until a uniform and non-adhesive pasty body is formed;
(3) Adding the pharmacological active ingredients into the paste, continuously stirring and mixing, sequentially adding microcrystalline cellulose, disodium phosphate, polyethylene glycol 6000 and sodium stearate, and continuously stirring until a uniform medicament solution is formed;
(4) Adding purified water to regulate the concentration of the medicament solution, and centrifuging the medicament solution filter box by utilizing a filter and a high-speed centrifuge to remove impurities so as to achieve the composite medicament with better purity and activity;
(5) The preparation of the medicament is finished, and the medicament is stored in a dry, light-proof and ventilated environment so as to ensure the maintenance of the quality of the medicament.
The compound medicament for inhibiting respiratory syncytial virus provided by the invention is further described by the following specific examples according to different raw material dosages.
Example 1
(1) Grinding 40% of Chinese medicinal components A and 10% of Chinese medicinal components B into fine powder respectively, and mixing uniformly;
(2) Adding the combined powder of the traditional Chinese medicine components A and B into 5% corn starch, stirring and mixing uniformly, gradually adding purified water, and stirring and mixing simultaneously until a uniform and non-adhesive paste is formed;
(3) Adding 5% of pharmacological active ingredient into the paste, continuously stirring and mixing, then adding 10% of auxiliary materials, and continuously stirring until a uniform medicament solution is formed;
(4) Adding purified water to regulate the concentration of the medicine solution, and centrifuging the medicine solution filtering box by using a filter and a high-speed centrifuge to remove impurities so as to obtain the composite medicine with better purity and activity.
Example 2
(1) Grinding 30% of Chinese medicinal component A and 15% of Chinese medicinal component B into fine powder respectively, and mixing uniformly;
(2) Adding the combined powder of the traditional Chinese medicine components A and B into 4% corn starch, stirring and mixing uniformly, gradually adding purified water, and stirring and mixing simultaneously until a uniform and non-adhesive paste is formed;
(3) Adding 10% of pharmacological active ingredient into the paste, continuously stirring and mixing, then adding 7% of auxiliary materials, and continuously stirring until a uniform medicament solution is formed;
(4) Adding purified water to regulate the concentration of the medicine solution, and centrifuging the medicine solution filtering box by using a filter and a high-speed centrifuge to remove impurities so as to obtain the composite medicine with better purity and activity.
Example 3
(1) Grinding 20% of Chinese medicinal components A and 20% of Chinese medicinal components B into fine powder respectively, and mixing uniformly;
(2) Adding the combined powder of the traditional Chinese medicine components A and B into 3% corn starch, stirring and mixing uniformly, gradually adding purified water, and stirring and mixing simultaneously until a uniform and non-adhesive paste is formed;
(3) Adding 15% of pharmacological active ingredient into the paste, continuously stirring and mixing, then adding 4% of auxiliary materials, and continuously stirring until a uniform medicament solution is formed;
(4) Adding purified water to regulate the concentration of the medicine solution, and centrifuging the medicine solution filtering box by using a filter and a high-speed centrifuge to remove impurities so as to obtain the composite medicine with better purity and activity.
Example 4
(1) Grinding 25% of Chinese medicinal component A and 17% of Chinese medicinal component B into fine powder respectively, and mixing uniformly;
(2) Adding the combined powder of the traditional Chinese medicine components A and B into 4% corn starch, stirring and mixing uniformly, gradually adding purified water, and stirring and mixing simultaneously until a uniform and non-adhesive paste is formed;
(3) Adding 13% of pharmacological active ingredient into the paste, continuously stirring and mixing, then adding 7% of auxiliary materials, and continuously stirring until a uniform medicament solution is formed;
(4) Adding purified water to regulate the concentration of the medicine solution, and centrifuging the medicine solution filtering box by using a filter and a high-speed centrifuge to remove impurities so as to obtain the composite medicine with better purity and activity.
Example 5
(1) Grinding 35% of Chinese medicinal components A and 13% of Chinese medicinal components B into fine powder respectively, and mixing uniformly;
(2) Adding the combined powder of the traditional Chinese medicine components A and B into 4% corn starch, stirring and mixing uniformly, gradually adding purified water, and stirring and mixing simultaneously until a uniform and non-adhesive paste is formed;
(3) Adding 7% of pharmacological active ingredient into the paste, continuously stirring and mixing, then adding 7% of auxiliary materials, and continuously stirring until a uniform medicament solution is formed;
(4) Adding purified water to regulate the concentration of the medicine solution, and centrifuging the medicine solution filtering box by using a filter and a high-speed centrifuge to remove impurities so as to obtain the composite medicine with better purity and activity.
TABLE 1 amounts of raw materials used in examples 1-5
In order to verify that the respiratory tract compound medicament prepared by the embodiment of the invention has a good antiviral effect, the compound medicament for inhibiting respiratory tract syncytial virus provided by the embodiment of the invention is illustrated by the following test examples.
Test examples
Test purpose: verifying the anti-syncytial virus effect of the drug;
test object: 120 mice infected with syncytial virus were used;
test sample: the respiratory tract compound medicament provided by the embodiments 1-5;
control sample: ribavirin;
the test steps are as follows: mice were equally divided into 6 groups, one control group and 5 test groups (A, B, C, D, E), corresponding to examples (1, 2,3,4, 5), respectively; each mouse is orally administrated with the medicine at a dose of 0.2ml/10g 1 time a day; the course of treatment was 7 days, and the condition and recovery of each group of mice was assessed daily; collecting lung tissues of mice and preparing pathological slides; observing and evaluating pathological sections, and determining the virus quantity and the lung lesion degree;
detection standard:
and (3) healing: the mice have no virus and the lungs have no lesions; the method is effective: the infection course and the virus amount of the mice are obviously reduced, and the lung lesion degree is also obviously reduced; invalidation: the infection course and the virus amount of the mice are not obviously changed, and the lung lesion degree is not obviously changed;
specific detection indexes are shown in Table 2.
TABLE 2
According to the respiratory tract compound medicament provided by the embodiments 1-5 of the invention, after the mice take the medicaments orally, the improvement effective rate is higher than 85%, the infection course and the virus amount of mice in a test group are obviously reduced, the lung lesion degree is obviously reduced, and the diffusion of HRSV can be effectively inhibited, compared with a control sample, the respiratory tract compound medicament provided by the invention has obvious effect, so that the respiratory tract compound medicament provided by the invention has better antiviral effect.
The foregoing has shown and described the basic principles, principal features and advantages of the invention. It will be understood by those skilled in the art that the present invention is not limited to the above-described embodiments, and that the above-described embodiments and descriptions are only preferred embodiments of the present invention, and are not intended to limit the invention, and that various changes and modifications may be made therein without departing from the spirit and scope of the invention as claimed. The scope of the invention is defined by the appended claims and equivalents thereof.
Claims (9)
1. A combination agent for inhibiting respiratory syncytial virus, comprising the following raw materials:
the traditional Chinese medicine component A accounts for 20-40% of the total mass;
the traditional Chinese medicine component B accounts for 10-20% of the total mass;
pharmacologically active ingredients, accounting for 5-15% of the total mass;
corn starch accounting for 3-5% of the total mass;
auxiliary materials accounting for 4-10% of the total mass;
the balance being purified water.
2. The complex agent for inhibiting respiratory syncytial virus according to claim 1, wherein: the Chinese medicinal component A comprises radix astragali, radix Platycodi and radix Puerariae.
3. The complex agent for inhibiting respiratory syncytial virus according to claim 2, wherein: the weight ratio of the astragalus, the platycodon grandiflorum and the radix puerariae is 6:2:1.
4. The complex agent for inhibiting respiratory syncytial virus according to claim 1, wherein: the Chinese medicinal component B comprises Glycyrrhrizae radix, semen Armeniacae amarum, ganoderma and radix Saposhnikoviae.
5. The complex agent for inhibiting respiratory syncytial virus according to claim 4, wherein: the weight ratio of the liquorice to the almond to the ganoderma lucidum to the divaricate saposhnikovia root is 2:2:2:1.
6. The complex agent for inhibiting respiratory syncytial virus according to claim 1, wherein: the pharmacological active ingredient adopts a virus inhibitor, and is suitable for inhibiting respiratory syncytial virus; the virus inhibitor is selected from oseltamivir and bismuth potassium citrate.
7. The complex agent for inhibiting respiratory syncytial virus according to claim 1, wherein: the auxiliary materials comprise microcrystalline cellulose, disodium phosphate, polyethylene glycol 6000 and magnesium stearate.
8. The complex agent for inhibiting respiratory syncytial virus according to claim 7, wherein: the weight ratio of the microcrystalline cellulose to the disodium phosphate to the polyethylene glycol 6000 to the magnesium stearate is 2:0.2:2:2.
9. A method for preparing a composite agent for inhibiting respiratory syncytial virus according to any one of claims 1-8, comprising the steps of:
s1, respectively grinding the traditional Chinese medicine component A and the traditional Chinese medicine component B into fine powder, and uniformly mixing;
s2, adding the combined powder of the traditional Chinese medicine components A and B into corn starch, stirring and mixing uniformly, gradually adding purified water, and stirring and mixing simultaneously until a uniform and non-adhesive paste is formed;
s3, adding the pharmacological active ingredients into the paste, continuously stirring and mixing, then adding auxiliary materials, and continuously stirring until a uniform medicament solution is formed;
s4, adding purified water to adjust the concentration of the medicament solution, and centrifuging the medicament solution filter box by utilizing a filter and a high-speed centrifuge to remove impurities so as to achieve the composite medicament with better purity and activity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311009766.1A CN116870047A (en) | 2023-08-11 | 2023-08-11 | Composite medicament for inhibiting respiratory syncytial virus and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311009766.1A CN116870047A (en) | 2023-08-11 | 2023-08-11 | Composite medicament for inhibiting respiratory syncytial virus and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116870047A true CN116870047A (en) | 2023-10-13 |
Family
ID=88268251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311009766.1A Pending CN116870047A (en) | 2023-08-11 | 2023-08-11 | Composite medicament for inhibiting respiratory syncytial virus and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116870047A (en) |
-
2023
- 2023-08-11 CN CN202311009766.1A patent/CN116870047A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10105408B2 (en) | Traditional Chinese medicine composition and preparation method and use thereof | |
| CN112294911A (en) | Traditional Chinese medicine composition for treating cough with lung heat | |
| CN111991480A (en) | Traditional Chinese medicine composition for preventing novel coronavirus pneumonia infection | |
| CN113995821B (en) | Chinese medicinal composition for treating pneumonia caused by novel coronavirus and other viruses, preparation and preparation method thereof | |
| CN116870047A (en) | Composite medicament for inhibiting respiratory syncytial virus and preparation method thereof | |
| WO2017129060A1 (en) | Medicine used for treating influenza, upper respiratory tract infection, viral pneumonia | |
| CN112168947A (en) | Traditional Chinese medicine composition for treating pneumonia and preparation method thereof | |
| CN107496558B (en) | Composition for treating cough and application thereof | |
| CN102552440B (en) | Anti-asthmatic and anti-inflammatory medicament and preparation method and application thereof | |
| CN1278709C (en) | Medicine for treating cold and its preparing process | |
| CN106880654B (en) | Application of panax japonicus extract in preparing medicine for treating rhinitis and composition | |
| CN112891482B (en) | A composition for treating coronavirus infection | |
| CN110585286A (en) | A topical unguent for treating dermatoses, and its preparation method | |
| CN1237998C (en) | Effervescence tablet for treating children's cough and asthma and its preparation | |
| CN109820826B (en) | Anti-inflammatory traditional Chinese medicine granules and preparation method thereof | |
| CN116211993B (en) | Composition for treating senile chronic disease and its preparation method | |
| CN108926672B (en) | Traditional Chinese medicine composition for treating systemic lupus erythematosus | |
| CN116785385B (en) | Traditional Chinese medicine composition for preventing and treating viral respiratory diseases | |
| CN104208213B (en) | A kind of Chinese-western medicine preparation treating chicken coccidiosis and preparation method thereof | |
| CN115006466B (en) | Traditional Chinese medicine preparation for treating eczema with damp-heat and yang deficiency and preparation method thereof | |
| CN113101331B (en) | Thyme herb tea and preparation method and application thereof | |
| CN112138105B (en) | Traditional Chinese medicine composition for treating bronchiectasis lung-spleen qi deficiency and phlegm-damp lung blocking syndrome and application thereof | |
| CN102579713B (en) | Traditional Chinese medicine for treating children obesity and preparation method | |
| CN1634340A (en) | Medicinal composition for preventing and treating children respiratory system diseases and preparation method thereof | |
| CN100551404C (en) | Medicament for inducing diuresis to alleviate edema preparation of compositions and detection method and purposes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |